NP
SRNE

NorthRock Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

NorthRock Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,055
Closed -$16.9K – 367
2022
Q4 		$16.9K Hold
19,055
– – ﹤0.01% 341
2022
Q3 		$30K Hold
19,055
– – ﹤0.01% 298
2022
Q2 		$38K Hold
19,055
– – ﹤0.01% 301
2022
Q1 		$44K Sell
19,055
-5,945
-24% -$18.5K ﹤0.01% 333
2021
Q4 		$116K Buy
+25,000
New +$155K 0.01% 324

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

NorthRock Partners's SRNE Position: Q1 2023 in Review

NorthRock Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 19,055 shares — an estimated $16.9K sold.

NorthRock Partners first reported a position in SRNE in Q4 2021 and held it in 5 quarters. The position peaked at $116K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • NorthRock Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • NorthRock Partners sold 19,055 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $16.9K.
  • NorthRock Partners first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 5 quarters.
  • NorthRock Partners's Sorrento Therapeutics, Inc. position peaked at $116K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on NorthRock Partners's 13F filing for Q1 2023, filed 4 May 2023.